Importance of Cellular Immunity and IFN-γ Concentration in Preventing SARS-CoV-2 Infection and Reinfection: A Cohort Study

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2023 Mar 30

PMID 36992500

Authors

Dragan Primorac

Petar Brlek

Eduard Stjepan Pavelic

Jana Mesic

David Glavas Weinberger

Vid Matisic

Vilim Molnar

Sasa Srica

Renata Zadro

Affiliations

Soon will be listed here.

Abstract

Recent studies have highlighted the underestimated importance of the cellular immune response after the emergence of variants of concern (VOCs) of SARS-CoV-2, and the significantly reduced neutralizing power of antibody titers in individuals with previous SARS-CoV-2 infection or vaccination. Our study included 303 participants who were tested at St. Catherine Specialty Hospital using the Quan-T-Cell SARS-CoV-2 in combination with the Quan-T-Cell ELISA (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany) for the analysis of IFN-γ concentration, and with Anti-SARS-CoV-2 QuantiVac ELISA IgG (Euroimmun Medizinische Labordiagnostika, Lübeck, Germany) for the detection of human antibodies of the immunoglobulin class IgG against the S1 domain of the SARS-CoV-2 spike protein. The statistical analysis showed a significant difference in the concentration of IFN-γ between reinfected participants and those without infection ( = 0.012). Participants who were not infected or reinfected with SARS-CoV-2 after vaccination and/or previous SARS-CoV-2 infection had a significantly higher level of cellular immunity. Furthermore, in individuals without additional vaccination, those who experienced infection/reinfection had significantly lower levels of IFN-γ compared to uninfected participants ( = 0.016). Our findings suggest a long-lasting effect of cellular immunity, measured by IFN-γ concentrations, which plays a key role in preventing infections and reinfections after the emergence of SARS-CoV-2 variants of concern.

Citing Articles

Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study.

Qin R, Feng Y, Zhang H, Zhao B, Lei W, Sun H JMIR Public Health Surveill. 2024; 10:e50846.

PMID: 39412952 PMC: 11498206. DOI: 10.2196/50846.

Designing the fusion protein of rotavirus VP8 and hepatitis A virus VP1 and evaluating the immunological response in BALB/c mice.

Yarmohammadi H, Aghasadeghi M, Sepahi A, Hamidi-Fard M, Bahramali G Iran J Microbiol. 2024; 16(3):401-410.

PMID: 39005596 PMC: 11245353. DOI: 10.18502/ijm.v16i3.15797.

Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case-Control Study.

Domenech-Montoliu S, Puig-Barbera J, Pac-Sa M, Orrico-Sanchez A, Gomez-Lanas L, Sala-Trull D Epidemiologia (Basel). 2024; 5(2):167-186.

PMID: 38651389 PMC: 11036210. DOI: 10.3390/epidemiologia5020012.

Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection.

Mihaescu G, Chifiriuc M, Filip R, Bleotu C, Ditu L, Constantin M Front Immunol. 2024; 14:1273604.

PMID: 38288121 PMC: 10822962. DOI: 10.3389/fimmu.2023.1273604.

Five doses of the mRNA vaccination potentially suppress ancestral-strain stimulated SARS-CoV2-specific cellular immunity: a cohort study from the Fukushima vaccination community survey, Japan.

Tani Y, Takita M, Wakui M, Saito H, Nishiuchi T, Zhao T Front Immunol. 2023; 14:1240425.

PMID: 37662950 PMC: 10469480. DOI: 10.3389/fimmu.2023.1240425.

References

Alsafi R . Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. Can J Infect Dis Med Microbiol. 2022; 2022:1156273. PMC: 9391183. DOI: 10.1155/2022/1156273. View

Todorovic-Rakovic N, Whitfield J . Between immunomodulation and immunotolerance: The role of IFNγ in SARS-CoV-2 disease. Cytokine. 2021; 146:155637. PMC: 8253693. DOI: 10.1016/j.cyto.2021.155637. View

von Massow G, Oh S, Lam A, Gustafsson K . Gamma Delta T Cells and Their Involvement in COVID-19 Virus Infections. Front Immunol. 2021; 12:741218. PMC: 8586491. DOI: 10.3389/fimmu.2021.741218. View

McMahan K, Yu J, Mercado N, Loos C, Tostanoski L, Chandrashekar A . Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020; 590(7847):630-634. PMC: 7906955. DOI: 10.1038/s41586-020-03041-6. View

Primorac D, Brlek P, Matisic V, Molnar V, Vrdoljak K, Zadro R . Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. Vaccines (Basel). 2022; 10(3). PMC: 8953558. DOI: 10.3390/vaccines10030442. View

Dan J, Mateus J, Kato Y, Hastie K, Yu E, Faliti C . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529). PMC: 7919858. DOI: 10.1126/science.abf4063. View

Bert N, Clapham H, Tan A, Chia W, Tham C, Lim J . Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med. 2021; 218(5). PMC: 7927662. DOI: 10.1084/jem.20202617. View

Ivashkiv L . IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018; 18(9):545-558. PMC: 6340644. DOI: 10.1038/s41577-018-0029-z. View

Castro F, Cardoso A, Goncalves R, Serre K, Oliveira M . Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion. Front Immunol. 2018; 9:847. PMC: 5945880. DOI: 10.3389/fimmu.2018.00847. View

10.

Costela-Ruiz V, Illescas-Montes R, Puerta-Puerta J, Ruiz C, Melguizo-Rodriguez L . SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020; 54:62-75. PMC: 7265853. DOI: 10.1016/j.cytogfr.2020.06.001. View

11.

Tang J, Novak T, Hecker J, Grubbs G, Zahra F, Bellusci L . Author Correction: Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022; 13(1):4732. PMC: 9372969. DOI: 10.1038/s41467-022-32572-x. View

12.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

13.

De Marco L, DOrso S, Pirronello M, Verdiani A, Termine A, Fabrizio C . Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals. JAMA Netw Open. 2022; 5(4):e2210871. PMC: 9034402. DOI: 10.1001/jamanetworkopen.2022.10871. View

14.

Wirsching S, Harder L, Heymanns M, Grondahl B, Hilbert K, Kowalzik F . Long-Term, CD4 Memory T Cell Response to SARS-CoV-2. Front Immunol. 2022; 13:800070. PMC: 9065554. DOI: 10.3389/fimmu.2022.800070. View

15.

Primorac D, Vrdoljak K, Brlek P, Pavelic E, Molnar V, Matisic V . Adaptive Immune Responses and Immunity to SARS-CoV-2. Front Immunol. 2022; 13:848582. PMC: 9114812. DOI: 10.3389/fimmu.2022.848582. View

16.

Ng O, Chia A, Tan A, Jadi R, Leong H, Bertoletti A . Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016; 34(17):2008-14. PMC: 7115611. DOI: 10.1016/j.vaccine.2016.02.063. View

17.

Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis J . SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022; 209:112911. PMC: 8824301. DOI: 10.1016/j.envres.2022.112911. View

18.

Brasu N, Elia I, Russo V, Montacchiesi G, Stabile S, De Intinis C . Memory CD8 T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination. Nat Immunol. 2022; 23(10):1445-1456. DOI: 10.1038/s41590-022-01313-z. View

19.

Muntjewerff E, Meesters L, van den Bogaart G . Antigen Cross-Presentation by Macrophages. Front Immunol. 2020; 11:1276. PMC: 7360722. DOI: 10.3389/fimmu.2020.01276. View

20.

Michlmayr D, Holm Hansen C, Gubbels S, Valentiner-Branth P, Bager P, Obel N . Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data. Lancet Reg Health Eur. 2022; 20:100452. PMC: 9245510. DOI: 10.1016/j.lanepe.2022.100452. View